Immuneering Corporation Increase (Decrease) in Accounts Payable
Immuneering Corporation (IMRX) reported Increase (Decrease) in Accounts Payable of $1.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- Immuneering Corporation increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.92M, a 61.89% increase year-over-year.
- Immuneering Corporation increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$89.58K.
- Immuneering Corporation increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $73.42K, a 29.39% increase year-over-year.
- Immuneering Corporation increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$974.89K.
- Immuneering Corporation increase (decrease) in accounts payable for fiscal 2025 was -$400.80K.
- Immuneering Corporation increase (decrease) in accounts payable for fiscal 2024 was -$112.14K.
- Immuneering Corporation increase (decrease) in accounts payable for fiscal 2023 was -$1.11M, a 162.88% decline from fiscal 2022.
- Immuneering Corporation increase (decrease) in accounts payable for fiscal 2022 was $1.76M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.83M 10-Q · filed 2026-08-05 | $1.91M derived: sum of 3 quarters · filed 2026-08-05 | $933.14K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$89.58K 10-Q · filed 2026-05-15 | -$16.16K derived: sum of 2 quarters · filed 2026-05-15 | -$991.06K derived: sum of 3 quarters · filed 2026-05-15 | $197.49K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $73.42K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$901.48K derived: sum of 2 quarters · filed 2026-03-06 | $287.07K derived: sum of 3 quarters · filed 2026-08-05 | -$400.80K 10-K · filed 2026-03-06 |
| 2025-09-30 | -$974.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $213.66K derived: sum of 2 quarters · filed 2026-08-05 | -$474.21K 10-Q · filed 2025-11-12 | -$417.47K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $500.68K 10-Q · filed 2026-08-05 | $557.42K derived: sum of 3 quarters · filed 2026-08-05 | -$122.03K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$687.87K 10-Q · filed 2026-05-15 | -$631.13K derived: sum of 2 quarters · filed 2026-05-15 | -$1.31M derived: sum of 3 quarters · filed 2026-05-15 | -$917.41K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $56.74K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$622.71K derived: sum of 2 quarters · filed 2026-03-06 | -$229.54K derived: sum of 3 quarters · filed 2026-03-06 | -$112.14K 10-K · filed 2026-03-06 |
| 2024-09-30 | -$679.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$286.28K derived: sum of 2 quarters · filed 2025-11-12 | -$168.88K 10-Q · filed 2025-11-12 | $1.68K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $393.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $510.57K 10-Q · filed 2025-08-13 | $681.14K derived: sum of 3 quarters · filed 2025-08-13 | -$97.06K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $117.39K 10-Q · filed 2025-05-05 | $287.96K derived: sum of 2 quarters · filed 2025-05-05 | -$490.24K derived: sum of 3 quarters · filed 2025-05-05 | -$558.57K derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $170.57K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$607.63K derived: sum of 2 quarters · filed 2025-03-20 | -$675.96K derived: sum of 3 quarters · filed 2025-03-20 | -$1.11M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$778.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$846.53K derived: sum of 2 quarters · filed 2024-11-13 | -$1.28M 10-Q · filed 2024-11-13 | -$461.29K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$68.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$499.26K 10-Q · filed 2024-08-06 | $316.92K derived: sum of 3 quarters · filed 2024-08-06 | $1.42M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$430.93K 10-Q · filed 2024-05-07 | $385.24K derived: sum of 2 quarters · filed 2024-05-07 | $1.48M derived: sum of 3 quarters · filed 2024-05-07 | $1.08M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $816.18K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $1.91M derived: sum of 2 quarters · filed 2024-03-01 | $1.51M derived: sum of 3 quarters · filed 2024-03-01 | $1.76M 10-K · filed 2024-03-01 |
| 2022-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $696.02K derived: sum of 2 quarters · filed 2023-11-09 | $944.04K 10-Q · filed 2023-11-09 | $499.03K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$402.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$154.10K 10-Q · filed 2023-08-03 | -$599.11K derived: sum of 3 quarters · filed 2023-08-03 | -$236.48K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $248.02K 10-Q · filed 2023-05-04 | -$196.99K derived: sum of 2 quarters · filed 2023-05-04 | $165.65K derived: sum of 3 quarters · filed 2023-05-04 | $229.37K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$445.01K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$82.38K derived: sum of 2 quarters · filed 2023-03-06 | -$18.66K derived: sum of 3 quarters · filed 2023-03-06 | -$130.40K 10-K · filed 2023-03-06 |
| 2021-09-30 | $362.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $426.36K derived: sum of 2 quarters · filed 2022-11-10 | $314.62K 10-Q · filed 2022-11-10 | $588.69K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $63.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$48.02K 10-Q · filed 2022-08-10 | $226.05K derived: sum of 3 quarters · filed 2022-08-10 | $535.69K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$111.74K 10-Q · filed 2022-05-10 | $162.33K derived: sum of 2 quarters · filed 2022-05-10 | $471.97K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $274.07K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $583.72K derived: sum of 2 quarters · filed 2022-03-10 | $1.19M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $309.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $911.52K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $601.87K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |